Eli Lilly and Company (NYSE:LLY) Sets New 52-Week High – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) hit a new 52-week high on Monday . The stock traded as high as $1,075.72 and last traded at $1,057.6320, with a volume of 497525 shares changing hands. The stock had previously closed at $1,059.70.

Analyst Ratings Changes

Several research firms recently issued reports on LLY. Scotiabank started coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target on the stock. Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a report on Monday, November 10th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their price target for the company from $886.00 to $1,104.00 in a research report on Monday, November 10th. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,047.50.

Eli Lilly and Company Stock Performance

The company has a 50-day simple moving average of $855.89 and a two-hundred day simple moving average of $787.81. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $1.01 trillion, a P/E ratio of 69.52, a PEG ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 EPS. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LLY. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the first quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth about $29,000. Steph & Co. grew its position in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. Finally, Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter valued at about $31,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.